Skip Navigation

Visiting Dana-Farber? See our prescreening and mask requirements.

  • The Center for Hematologic Oncology at Dana-Farber Brigham Cancer Center is one of the largest programs in the U.S. for patients with hematologic malignancies. We see more than 12,500 patients each year from around the world, and we offer specialized expertise in:

    • Acute and chronic leukemia
    • Chronic lymphocytic leukemia (CLL)
    • Aggressive lymphoma
    • Low-grade lymphoma
    • Mastocytosis
    • Autologous and allogeneic stem cell transplant
    • Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
    • Histiocytosis
    • Multiple myeloma
    • Precursor conditions
    • Waldenström's macroglobulinemia
    • Cellular therapies such as CAR T-cell therapy

    Our faculty and staff are actively engaged in basic, translational, and clinical research to improve outcomes and quality of life for patients. We offer more than 200 clinical trials evaluating new therapies — making us the first to offer the most promising treatments to patients.

    Why Choose Dana-Farber Brigham Cancer Center for Stem Cell Transplant or CAR T-Cell Therapy

    Our Stem Cell Transplant and Cellular Therapies Program has more than 45 years of experience and is one of the largest in the world, having performed more than 11,180 transplants. This experience makes a difference:

    • In-depth knowledge: We understand how to manage the complex treatment plans and unique needs associated with transplant and other cellular therapies.
    • Extensive evaluation: Our team carefully evaluates each patient to determine if stem cell transplant or CAR T-cell therapy is appropriate.
    • Exceptional outcomes: Our stem cell transplant outcomes consistently exceed the expected outcomes as established by the Center for International Blood and Marrow Transplant Research (CIBMTR).
    • Large team: We have more than 35 transplant-credentialed physicians. All are Harvard Medical School faculty members.
    • Disease-specific expertise: We offer stem cell transplant for many types of blood cancer and blood disorders, including leukemias, lymphomas, multiple myeloma, myelodysplastic syndromes, aplastic anemia, sickle cell disease, and more. Learn more about the diseases we treat with stem cell transplant.
    • Novel approaches: Our Center offers all FDA-approved CAR T-cell therapies, as well as clinical trials exploring this CAR T and other cellular therapies for blood cancers and solid tumors.
    • State-of-the-art, in-house cell processing lab: The Connell and O'Reilly Families Cell Manipulation Core Facility is a critical component to our program, processing cellular products for stem cell transplant and CAR T-cell therapies.
    • Strong partnerships: Dana-Farber partners with Brigham and Women's Hospital, one of the nation's leading hospitals, to care for patients. In addition to a dedicated transplant or cellular therapy physician and nurse practitioner, patient care may include expert specialists in infectious disease, dermatology, neurology, pulmonology, and more – all with a deep understanding of the complex needs and complications of patients receiving these advanced therapies.

    What We Offer to International Patients

    From exceptional medical care to support with housing and other logistics, we offer many services to international patients:

    Program Leaders

    Our physician, nursing, and administrative teams are leaders in national and international organizations, working to influence policy and improve standards of care.

    Robert J. Soiffer, MD
    Chief, Division of Hematologic Malignancies
    Vice Chair, Department of Medical Oncology

    Catherine Wu, MD
    Chief, Division of Stem Cell Transplantation and Cellular Therapies

    Stem Cell Transplant Leadership

    Joseph Antin, MD
    Chief, Stem Cell Transplantation Emeritus

    Corey Cutler, MD, MPH, FRCPC
    Medical Director, Stem Cell Transplantation
    Director of Clinical Research, Stem Cell Transplantation
    Director, Stem Cell Transplantation Survivorship Program

    Vincent Ho, MD
    Director of Clinical Operations, Stem Cell Transplantation

    John Koreth, MBBS, DPhil
    Director of Translational Research, Stem Cell Transplantation

    Rizwan Romee, MD
    Director, Haploidentical Transplantation Program

    Amy Emmert, MScPH
    Executive Director for Cellular Therapy External Affairs

    Janet Bagley, RN, MS
    Associate Chief Nurse

    Julie Porter
    Vice President of Cellular Therapy Operations

    Meet Our Stem Cell Transplant Team.

    Cellular Therapies Leadership

    Caron Jacobson, MD
    Medical Director, Immune Effector Cell Therapy Program

    Sarah Nikiforow, MD, PhD
    Technical Director, Immune Effector Cell Therapy Program
     Medical Director, Connell and O'Reilly Families Cell Manipulation Core Facility

    Jerome Ritz, MD
    Executive Director, Connell and O'Reilly Families Cell Manipulation Core Facility

    Linda Caruso, NP
    Assistant Program Director, Immune Effector Cell Therapy Program

    How to Refer a Patient

    We work with our partners in the Brigham and Women's Hospital International Office to coordinate referrals for international patients. Contact us to inquire about an appointment:

    Phone: +1-617-732-5777
    Fax: +1-617-264-5100

    Post-Treatment Care and Coordination

    Care for stem cell transplant or CAR T-cell therapy patients continues long after they are discharged from the hospital and return home to your care. We provide physicians with post-discharge care guidelines that outline recommended testing, symptoms to monitor, re-immunizations, and more — all to help you care for your returning patients. And our physicians will remain available to consult with you and answer any questions about post-discharge care.